PMID- 38089404
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231213
IS  - 2770-9183 (Electronic)
IS  - 2770-9191 (Print)
IS  - 2770-9183 (Linking)
VI  - 2
IP  - 3
DP  - 2023 Jun
TI  - Third-line or above anlotinib in relapsed and refractory small cell lung cancer 
      patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, 
      double-blind phase 2 study.
PG  - 181-190
LID - 10.1002/cai2.43 [doi]
AB  - BACKGROUND: The prognosis of patients with small cell lung cancer (SCLC) and 
      brain metastases (BM) was poor. This study aimed to explore the efficacy and 
      safety of anlotinib as third-line or above treatment in SCLC with BM. METHODS: 
      This was a subgroup analysis of the ALTER1202 trial, which was a randomized, 
      placebo-controlled trial aimed to evaluate the role of anlotinib as third-line 
      treatment or above in patients with SCLC. This study included patients with BM at 
      baseline. The efficacy and safety outcomes included progression-free survival 
      (PFS), overall survival (OS), central nervous system (CNS), objective response 
      rate (ORR), CNS disease control rate (DCR), time to CNS progression, and adverse 
      events (AEs). RESULTS: Twenty-one and nine patients with BM were included in the 
      anlotinib and placebo groups, respectively. The median PFS and OS were 3.8 months 
      (95% confidence interval [CI]: 1.8-6.1) and 6.1 months (95% CI: 4.1-8.0) in the 
      anlotinib group. Anlotinib was associated with a significant improvement in PFS 
      (hazard ratio [HR] = 0.15, 95% CI: 0.04-0.51, p = 0.0005) and OS (HR = 0.26, 
      95% CI: 0.09-0.73, p = 0.0061) than placebo. Anlotinib significantly prolonged 
      the time to CNS progression (p < 0.0001). The anlotinib group had a higher CNS 
      DCR than placebo (95.2% vs. 22.2%, p = 0.0001). The most common grade 3 or higher 
      AEs were increased lipase (19.0%), hypertension (14.3%), and hyponatremia (14.3%) 
      in the anlotinib group. CONCLUSIONS: Anlotinib proved to have potential CNS 
      activity and a manageable toxicity profile in patients with SCLC and BM, 
      significantly delaying CNS progression.
CI  - (c) 2023 The Authors. Cancer Innovation published by John Wiley & Sons Ltd. on 
      behalf of Tsinghua University Press.
FAU - Cheng, Ying
AU  - Cheng Y
AUID- ORCID: 0000-0001-9908-597X
AD  - Department of Thoracic Medical Oncology Jilin Cancer Hospital Changchun China.
FAU - Wang, Qiming
AU  - Wang Q
AD  - Department of Internal Medicine Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital Zhengzhou China.
FAU - Li, Kai
AU  - Li K
AD  - Department of Pulmonary Oncology Tianjin Medical University Cancer Hospital 
      Tianjin China.
FAU - Shi, Jianhua
AU  - Shi J
AD  - Department of Medical Oncology Linyi Cancer Hospital Linyi China.
FAU - Han, Baohui
AU  - Han B
AD  - Department of Respiratory Medicine, Shanghai Chest Hospital Shanghai Jiaotong 
      University Shanghai China.
FAU - Wu, Lin
AU  - Wu L
AD  - Department of Thoracic Medical Oncology Hunan Cancer Hospital Changsha China.
FAU - Chen, Gongyan
AU  - Chen G
AD  - Department of Respiratory Medicine Harbin Medical University Cancer Hospital 
      Harbin China.
FAU - He, Jianxing
AU  - He J
AD  - Department of Thoracic Surgery The First Affiliated Hospital of Guangzhou Medical 
      University Guangzhou China.
FAU - Wang, Jie
AU  - Wang J
AD  - Department of Thoracic Medical Oncology Cancer Hospital Chinese Academy of 
      Medical Sciences Beijing China.
FAU - Qin, Haifeng
AU  - Qin H
AD  - Department of Pulmonary Oncology The Fifth Medical Centre of Chinese PLA General 
      Hospital Beijing China.
FAU - Li, Xiaoling
AU  - Li X
AD  - Department of Medical Oncology Liaoning Cancer Hospital and Institute Shenyang 
      China.
LA  - eng
PT  - Journal Article
DEP - 20230117
PL  - England
TA  - Cancer Innov
JT  - Cancer innovation
JID - 9918713888606676
PMC - PMC10686170
OTO - NOTNLM
OT  - advanced small cell lung cancer
OT  - angiogenesis inhibitors
OT  - anlotinib
OT  - brain metastasis
OT  - safety
COIS- The authors declare no conflict of interest.
EDAT- 2023/12/13 18:42
MHDA- 2023/12/13 18:43
PMCR- 2023/01/17
CRDT- 2023/12/13 12:50
PHST- 2022/10/21 00:00 [received]
PHST- 2022/11/17 00:00 [revised]
PHST- 2022/11/24 00:00 [accepted]
PHST- 2023/12/13 18:43 [medline]
PHST- 2023/12/13 18:42 [pubmed]
PHST- 2023/12/13 12:50 [entrez]
PHST- 2023/01/17 00:00 [pmc-release]
AID - CAI243 [pii]
AID - 10.1002/cai2.43 [doi]
PST - epublish
SO  - Cancer Innov. 2023 Jan 17;2(3):181-190. doi: 10.1002/cai2.43. eCollection 2023 
      Jun.